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Bone metastasis is known as a poor prognostic factor in colorectal cancer (CRC), but its clinical 
manifestations and outcomes are uncertain. CRC with bone metastasis was searched from January 
2006 to April 2016. Of 11,551 CRC patients, 321 (2.7%) patients had bone metastasis. Bone‑only 
metastasis was found in only 8.7% of patients. Synchronous bone metastasis was present in 147 
(45.8%) patients. In patients with metachronous bone metastasis, the median time from CRC 
diagnosis to bone metastasis (TTB) was 27.2 months. KRAS mutation status was a marginally 
significant factor affecting TTB (median TTB, KRAS wild‑type or mutation: 29 or 25.8 months, 
respectively, P = 0.068). Skeletal‑related events (SREs) were noted in 200 (62.3%) patients. Median 
overall survival (OS) from diagnosis of bone metastasis was 8.0 months. On multivariate analysis, 
multi‑organ metastasis, peritoneal metastasis, neutrophil‑to‑lymphocyte ratio (NLR) ≥ 2.7, and 
alkaline phosphatase (ALP) ≥ 123 were independent factors for OS. Palliative chemotherapy prolonged 
survival in CRC patients with bone metastasis (HR 0.25, 95% CI 0.2–0.33). In conclusion, bone 
metastasis of CRC is rare, but it is related to SREs. Most patients have other organ metastasis and 
survival is 8.0 months. Attention should be paid to bone metastasis in CRC patients.
Colorectal cancer (CRC) was the fourth most common cancer in the United States, with a total of 101,420 cases 
of newly diagnosed CRC in  20191. The most common metastatic sites were liver (70%) and lung (37%)2. Bone 
metastasis was observed in 1.2–12% of patients with CRC. The ten-year incidence of bone metastasis from 
CRC has been reported to be 2.7%3,4. Recently, bone metastasis incidence has increased due to improvement of 
survival of patients with metastatic CRC and diagnostic imaging  techniques5. Bone metastasis of CRC is related 
to poor survival outcome. The median survival of patients with bone metastasis of CRC ranges from 7 months 
to 9.4  months6–8. Previous studies have reported that multiple bone metastases, lung metastasis, and elevated 
carcinoembryonic antigen (CEA) are poor prognostic factors in CRC patients. However, these factors have not 
been universally observed in previous reports. The prognostic factors of patients with bone metastasis are still 
uncertain. A prognostic model has not been suggested yet. In addition, the role of palliative chemotherapy in 
CRC patients with bone metastasis has been rarely studied.
KRAS mutations have been detected in 40–50% of patients with CRC 9,10. KRAS mutations at codon 12 or 13 
account for approximately 90% of all mutation types. In general, clinical behaviors are more aggressively pre-
sented in patients with KRAS mutations. Recurrence-free survival is significantly worse and lung metastasis is 
significantly higher in CRC patients with KRAS  mutations11–13. Although the prognostic value of KRAS mutations 
is still controversial, some studies have revealed that KRAS mutations are associated with poorer  survival12,14–16. 
However, associations between KRAS mutations and bone metastases have not been reported yet.
Thus, the aim of this study was to explore the clinical features of CRC patients with bone metastasis, including 
time to bone metastasis (TTB), metastatic sites of bone, and skeletal-related events (SREs) by KRAS mutation 
status. In addition, prognostic factors for CRC with bone metastasis were evaluated, and a prognostic model for 
survival was also suggested.
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Results
Patient characteristics. Of 11,551 CRC patients, colon cancer (7242, 62.7%) and rectal cancer (4309, 
37.3%) with bone metastasis were diagnosed in 192 (2.7%) patients and 129 (3.0%) patients, respectively. Patient 
characteristics are shown in Table 1. Their median age was 61 years old. There were 188 (58.6%) male patients. 
Colon cancer was slightly predominant (59.8%). Similar metastatic pattern were observed in both the synchro-
Table 1.  Characteristics of CRC with bone metastasis according to KRAS mutation status. CRC colorectal 
cancer, CTx chemotherapy, NLR neutrophil–lymphocyte ratio, SRC signet ring cell carcinoma, ALP alkaline 
phosphatase, CEA carcinoembryonic antigen, No number. a Other bone include skull, rib, scapula, knee, 




Wild type Mutant type
P-valueNo. (321) % No. (126) % No. (78) %
Age (Median, range) 61 28–87 58 29–83 62 28–79 0.007
Sex
Male 188 58.6 81 64.3 38 48.7 0.028
Female 133 41.4 45 35.7 40 51.3
Primary site
Colon 192 59.8 79 62.7 48 61.5 0.868
Rectum 129 40.2 47 37.3 30 38.5
Tumor sideness
Left side 250 77.9 105 84.7 55 71.4 0.023
Right side 63 19.6 19 15.3 22 28.6
Metastasis pattern
Synchronous 147 45.8 55 43.7 31 39.7 0.583
Metachronous 174 54.2 71 56.3 47 60.3
Histologic type
Adenocarcinoma 292 91 114 90.5 73 93.6 0.325
SRC 14 4.4 7 5.6 1 1.3
Mucinous carcinoma 15 4.7 5 4 4 5.1
Clinical stage at CRC diagnosis
1 or 2 19 5.9 7 5.7 6 7.7 0.283
3 68 21.2 32 26 13 16.7
4 229 71.3 84 68.3 59 75.6
Bone only metastasis
Yes 28 8.7 9 7.1 2 2.6 0.211
No 293 91.3 117 92.9 76 97.4
Other organ metastasis
Liver metastasis
No 137 42.7 59 46.8 22 28.2 0.008
Yes 184 57.3 67 53.2 56 71.8
Lung metastasis
No 153 47.7 63 50 28 35.9 0.049
Yes 168 52.3 63 50 50 64.1
Peritoneal metastasis
No 243 75.7 90 71.4 60 76.9 0.387
Yes 78 24.3 36 28.6 18 23.1
Brain metastasis
No 306 95.3 122 96.8 70 89.7 0.062
Yes 15 4.7 4 3.2 8 10.3
Site of bone metastasis
Spine
No 100 31.2 37 29.4 29 37.2 0.246
Yes 221 68.8 89 70.6 49 62.8
Pelvis
No 155 48.3 60 47.6 39 50
Yes 166 51.7 66 52.4 39 50
Long bone
No 252 78.5 100 79.4 62 79.5 0.983
Yes 69 21.5 26 20.6 16 20.5
Other  bonea
No 197 61.4 79 62.7 50 64.1 0.84
Yes 124 38.6 47 37.3 28 35.9
Laboratory values at diagnosis of bone metastasis (median, 
range)
NLR 3.5 0.4–31.8 3.5 0.6–19.7 3.6 0.8–31.8 0.937
Platelet (× 1000/uL) 247 25–654 243 26–637 245 25–654 0.903
ALP (IU/L) 114 17–1509 98 17–897 136 32–1509 0.025
CEA (ng/mL) 75.4 0.4–20,000 77.7 0.4–20,000 159.3 2.3–20,000 0.041
Palliative CTx
Irinotecan based 96 29.9 47 37.3 32 41 0.136
Oxaliplatin based 73 22.7 33 26.2 10 12.8
Othersb 43 13.4 16 12.7 11 14.1
No 109 34 30 23.8 25 32.1
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nous and metachronous groups. There were 292 (91%) cases of adenocarcinoma. A total of 229 (71.3%) patients 
were classified as stage 4 at the initial time of CRC diagnosis. Bone-only metastasis occurred in 28 (8.7%) patients. 
Frequently observed metastatic sites of bone included the spine (68.8%) and pelvis (51.7%). Median laboratory 
values of neutrophil-to-lymphocyte ratio (NLR), platelet count, alkaline phosphatase (ALP), and CEA at the 
time of bone metastasis were 3.5, 247 × 103/μL, 114 IU/L, and 75.4 ng/mL, respectively. Of patients whose KRAS 
mutation status was revealed, 126 (61.8%) patients had wild-type KRAS, while 78 (38.2%) patients had KRAS 
mutations. According to the presence of KRAS mutation, old age, females, and right-sided colon cancer patients 
were statistically predominant in the group with KRAS mutation. In addition, liver metastasis, lung metastasis, 
high ALP level and high CEA level were frequently observed at the time of bone metastasis in the group with 
KRAS mutation. Codon 12 mutation, codon 13 mutation, and mutation site unknown accounted for 58, 16, and 
4 cases, respectively. Clinical differences by KRAS mutation type and tumor sidedness were also analyzed in Sup-
plementary Tables S1 and S2. A total of 212 (66%) patients received palliative chemotherapy.
Natural course of bone metastasis. Metachronous bone metastasis occurred in 174 (54.2%) patients 
(Fig. 1). In metachronous bone metastasis patients, the median TTB was 27.2 months. TTB was analyzed by 
clinical factors (Table 2). The median TTB in patients with initial clinical stages 1/2, 3, and 4 were 35.9, 28.8, and 
20.9 months, respectively (P < 0.001). KRAS mutation status was a marginally significant factor affecting time 
Figure 1.  Time to bone metastasis from colorectal cancer (CRC) diagnosis according to KRAS mutation status.
Table 2.  Median time from primary cancer diagnosis to bone metastasis in metachronous patients. SRC signet 
ring cell carcinoma, No number, CI confidence interval.
Categorical No. of patients Median time (months) 95% CI P-value
Age
 < 61 92 27.4 24.5 30.3 0.171
 ≥ 61 82 25.7 20.7 30.7
Sex
Male 106 27.3 23.9 30.7 0.831
Female 68 25.8 20.2 31.4
Primary site
Colon 91 25.9 21.9 29.9 0.498
Rectum 83 28.3 25 31.6
KRAS mutation
Wild type 71 29 23.5 34.5 0.068
Mutant type 47 25.8 15.9 35.7
Tumor sideness
Left side 143 28.3 25.5 31.1 0.457
Right side 29 22.6 14.0 31.2
Histologic type
Adenocarcinoma or SRC 164 27.4 24.8 30.0 0.269
Mucinous carcinoma 10 16.2 11.1 21.3
Initial clinical stage
1 or 2 19 35.9 23.2 48.6  < 0.001
3 68 28.8 24.1 33.5
4 82 20.9 16.3 25.5
Overall 174 27.2 24.2 30.2
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to bone metastasis. Patients with KRAS wild-type or mutation had a median TTB of 29 months or 25.8 months, 
respectively (P = 0.068). In addition, mucinous carcinoma had a shorter tendency of time to bone metastasis 
compared with that of non-mucinous carcinoma (median TTB, 16.2 months vs. 27.4 months, P = 0.269). SREs, 
pathological fractures, spinal cord compression, surgery to bone, radiotherapy to bone, and hypercalcemia were 
observed in 26 (8.1%), 28 (87%), 43 (13.4%), 183 (57%), and 12 (3.7%) patients, respectively (Table 3). There 
was no significant difference in the SRE pattern between patients with KRAS wild-type and patients with KRAS 
mutation.
Survival analysis. The median follow-up time was 7.4 months. The median OS from diagnosis of bone 
metastasis was 8.0  months (95% confidence interval (CI) 6.8–9.2  months). The statistically determined best 
cut-off point of NLR was 2.7. Survival was significantly extended in patients with low levels of NLR or ALP com-
pared to patients with high levels of NLR or ALP (median OS, NLR: 12.2 months vs. 5.6 months, P < 0.001; ALP: 
11.2 months vs. 5.2 months, P < 0.001; Fig. 2A,B). Patients with bone-only metastasis had the longest median OS 
of 20.4 months (Fig. 2C). Peritoneal carcinomatosis showed poor survival outcome (median OS: 9.2 months vs. 
4.3 months, P < 0.001) (Fig. 2D). However, KRAS mutation status did not significantly affect survival outcome 
(median OS: wild-type vs. mutant type, 9.2 months vs. 8.4 months, P = 0.083).
According to univariate analysis, primary site; tumor sidedness; bone metastasis pattern (bone-only or multi-
organ metastasis); presence of liver, lung or peritoneal metastasis; NLR; ALP level; and CEA level were all associ-
ated with OS at p-value < 0.05 (Table 4). Multivariate analysis demonstrated that multi-organ metastasis (Hazard 
ratio (HR) 2.43; 95% CI 1.39–4.25), peritoneal metastasis (HR 1.47; 95% CI 1.08–2.02), NLR ≥ 2.7 (HR 1.54; 
95% CI 1.17–2.04), and ALP ≥ 123 (HR 1.76; 95% CI 1.32–2.34) were independent factors for OS. Bone-only 
metastasis was a prognostic factor with the highest hazard ratio for OS.
Prognostic model analysis. We divided patients into two subgroups based on four independent prog-
nostic factors for OS: 171 patients with 0 to 2 adverse prognostic factors (low-risk group) and 122 patients with 
three to four adverse prognostic factors (high-risk group). These risk groups were significantly associated with 
OS (median OS for low- and high-risk groups: 11.9 months and 4.1 months, respectively, P < 0.001) (Fig. 3A). 
Regardless of the risk group, palliative chemotherapy had a benefit for OS in patients with bone metastasis. 
Among 171 low-risk patients, 123 (71.9%) patients received palliative chemotherapy. As shown in Fig.  3B, 
patients treated with palliative chemotherapy had longer OS than patients who received the best supportive 
care, including radiotherapy (median OS: 16.7 months vs. 4.3 months respectively, P < 0.001). Among 122 high-
risk patients, OS was also longer in the palliative chemotherapy group (median OS: 6.8 months vs. 2.3 months, 
P < 0.001) (Fig. 3C).
Discussion
Bone metastasis of CRC is rare, but it is related to SREs. Most patients have other organ metastasis and survival is 
8.0 months in unselected patients. KRAS mutation affected different clinical manifestations in these patients. We 
showed that patients with KRAS mutation had a tendency to have shorter time to bone metastasis than patients 
with wild-type KRAS, but there were no significant survival differences between patients with KRAS wild-type 
and those with KRAS mutation. Several prognostic factors were noted in this study. Patients who received pallia-
tive chemotherapy showed prolonged survival compared to patients with supportive care, especially in patients 
with less adverse factors.
The observed frequency of bone metastasis in CRC was 1.2–12%, with a wide  range3,4. Each study included 
CRC with bone metastasis in various clinical settings dealing with resected patients or metastatic patients. It 
might be related to the wide range of bone metastasis incidence in CRC patients. Recently, systemic chemo-
therapy was more effective and survival was prolonged. In addition, diagnostic modality such as positron emis-
sion tomography (PET) coupled with computed tomography (CT) scan (PET-CT) was developed and possibility 
of bone metastasis detection would be increased. Asymptomatic bone metastasis could be detected on routine 
follow-up. It might help prevent SREs, but it has a possibility of overtreatment, such as chemotherapy regimen 
change or radiotherapy. Therefore, the role of asymptomatic bone metastasis detection should be investigated in 











P-valueNo % No % No %
SRE, total 200 62.3 81 64.3 55 70.5 0.359
Pathologic fracture 26 8.1 12 9.5 6 7.7 0.654
Spinal cord compression 28 8.7 13 10.3 8 10.3 0.989
Surgery to bone 43 13.4 19 15.1 12 15.4 0.953
Radiotherapy to bone 183 57 75 59.5 51 65.4 0.403
Hypercalcemia 12 3.7 5 4 6 7.7 0.34
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further studies. In contrast, surveillance cannot be performed until death in various circumstances, and routine 
follow-up schemes without bone scintigraphy or PET-CT may not detect bone metastasis. These factors are 
related to the underdiagnosis of bone metastasis.
In clinical practice, at the time of bone metastasis, multi-organ metastases were frequently observed. Bone-
only metastasis was found in only 8.7% of subjects, and 91.3% of patients had other organ metastasis in this 
study. Commonly observed multi-organ metastases might be related to the poor prognosis in bone  metastasis5. 
KRAS mutation has been studied as a metastasis promoting factor in CRC. The results of our study also showed 
that patients with KRAS mutation had a higher frequency of both lung and liver metastases at the time of bone 
metastasis. In addition, patients with KRAS mutation more frequently had high ALP and high CEA levels. 
Regarding KRAS mutation type (codon 12 vs. codon 13), there were no significant clinical differences between 
these two groups, except the NLR level.
The median time to bone metastasis was 27.2 months in metachronous patients. Time to bone metastasis 
was shorter in patients with KRAS mutation compared to patients with wild type KRAS, although it was not 
statistically significant. It has been reported that KRAS mutation can lead to shorter time to metastasis in liver, 
lung, and  bone17. Initial CRC stage was also a significant factor for time to bone metastasis. Based on our data, 
first surveillance for identification of bone metastasis might be considered within 2 years after primary CRC 
diagnosis and attention is needed, especially in patients with initial stage 4. Additional evaluation and close 
monitoring 2 years after CRC diagnosis should also be performed.
Risk factors for bone metastasis in CRC have been reported in many  studies8. Primary tumor location, tumor 
stage and histologic type were revealed as significant risk factors for bone metastasis. Regarding tumor location, 
Figure 2.  Kaplan–Meier curves of overall survival (OS) for all patients (n = 321) according to prognostic 
factors: (A) neutrophil-to-lymphocyte ratio (NLR), (B) alkaline phosphatase (ALP), (C) bone-only metastasis, 
and (D) peritoneal metastasis.
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Table 4.  Univariate and multivariate analysis using cox regression for OS. NLR neutrophil–lymphocyte ratio, 
ALP alkaline phosphatase, CEA carcinoembryonic antigen, CTx chemotherapy, SRC signet ring cell carcinoma, 
OS overall survival, No number, HR hazard ratio, CI confidence interval.
Categorical
Univariate Multivariate
No. of patients HR 95% CI P-value HR 95% CI P-value
Age
 < 61 154 1 0.057
 ≥ 61 167 1.26 0.99 1.59
Sex
Male 188 1 0.876
Female 133 0.98 0.77 1.25
Primary site
Colon 192 1 0.041
Rectum 129 0.78 0.61 0.99
KRAS mutation
Wild type 126 1 0.085
Mutant type 78 1.31 0.96 1.79
Tumor sideness
Left side 250 1 0.018
Right side 63 1.44 1.06 1.94
Metastasis pattern
Synchronous 147 1 0.815
Metachronous 174 0.97 0.77 1.23
Histologic type
Adenocarcinoma 292 1 0.727
SRC 14 1.15 0.66 2.00
Mucinous carcinoma 15 0.84 0.48 1.47
Bone-only metastasis
Yes 28 1  < 0.001 1 0.002
No 293 3.02 1.88 4.87 2.43 1.39 4.25
Liver metastasis
No 137 1  < 0.001
Yes 184 1.87 1.45 2.40
Lung metastasis
No 153 1 0.022
Yes 168 1.32 1.04 1.67
Peritoneal metastasis
No 243 1  < 0.001 1 0.016
Yes 78 2.05 1.56 2.71 1.47 1.08 2.02
Brain metastasis
No 306 1 0.172
Yes 15 1.46 0.85 2.50
NLR
 < 2.7 110 1  < 0.001 1 0.002
 ≥ 2.7 195 1.72 1.33 2.21 1.54 1.17 2.04
ALP (IU/L)
 < 123 159 1  < 0.001 1  < 0.001
 ≥ 123 135 2.17 1.67 2.81 1.76 1.32 2.34
CEA (ng/mL)
 < 5 37 1  < 0.001
 ≥ 5 253 2.29 1.52 3.45
Palliative CTx
No 109 1  < 0.001
Yes 212 0.25 0.20 0.33
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other studies have shown that rectal cancer had a greater chance of bone metastasis than colon cancer. Although 
our studies showed more of a tendency for bone metastasis in rectal cancer compared to that in colon cancer, 
there was no significant difference between the two groups (P = 0.28). This study included all CRC patients 
treated in our institution, and the distribution of clinical factors, such as stage and histology, may have affected 
the results in the two groups.
The prognosis of bone metastasis in CRC patients was poor. The median survival of these patients was 
approximately 8  months7,18. Prognostic factors for bone metastasis in CRC have been evaluated in several studies. 
Multiple bone metastases, primary site of colon/lung metastasis, and elevated CEA level have been identified as 
poor prognostic factors. In our study, four prognostic factors were revealed: multi-organ metastasis, peritoneal 
metastasis, high NLR (≥ 2.7), and high ALP (≥ 123 IU/L). Of these factors, whether a patient had bone-only 
metastasis was a prognostic factor with the highest hazard ratio for OS (HR 2.43; 95% CI 1.39–4.25). The median 
survival was 7.8 months for patients with other organ metastasis and 20.4 months for those with bone-only 
metastasis. We also made a prognosis scoring model using the four independent factors. Risk group was catego-
rized as low-risk (score 0–2) and high-risk (score 3–4) groups. The median survival of the low-risk group was 
11.9 months. It was almost 1.5-fold (4 months longer) than that of unselected CRC patients with bone metastasis.
Bone metastasis is an important factor for quality of life and survival. Proper treatment, including radio-
therapy, surgery and medical therapy, improves bone metastasis symptoms, such as pain, and bisphosphonates 
could delay the development of  SREs8. In addition, bone metastasis has been known to be a poor prognostic factor 
in metastatic CRC. In our study, palliative chemotherapy provided patients a chance to increase survival up to 
16.7 months in the low-risk group. The high-risk group also had a survival gain from palliative chemotherapy, 
although the survival benefit was less than the low-risk group. We had to pay attention to the interpretation of 
this survival data analyzed by the presence of chemotherapy, because patients who did not receive chemotherapy 
might have poor performance status or comorbidities, which might be related to poor prognosis. Our results 
suggest the possibility of chemotherapy benefit in bone metastasis patients, and predictive markers for chemo-
therapy should be further studied. A prognosis scoring model might help predict the survival for CRC patients 
with bone metastasis and guide treatment decisions, including palliative chemotherapy, or the best supportive 
care according to their benefits.
This study had several limitations. First, it was a retrospective study. Thus, the performance status could not 
be identified. Second, this study did not evaluate the impact of bisphosphonates on SREs. Bisphosphonates are 
not reimbursed in Korea. They are only permitted in hypercalcemia secondary to CRC. However, this study also 
has its strengths. Large numbers of patients were enrolled, and KRAS mutation status and tumor sidedness were 
analyzed to identify their roles in bone metastasis of CRC. In conclusion, bone metastasis of CRC is rare, but it 
is related to SREs. Most patients have other organ metastasis and survival is 8.0 months in unselected patients. 
It should receive more attention from clinicians. Time to bone metastasis and prognosis were not different 
according to KRAS mutation status in our study. Surveillance for bone metastasis might be considered in the 
first 2 years after CRC diagnosis, and additional evaluation and close monitoring 2 years after the CRC diagnosis 
should be performed. According to our prognosis scoring model, a patient’s prognosis could be predicted, and 
it may help to guide palliative chemotherapy in CRC with bone metastasis.
Methods
Patient selection. From January 2006 to April 2016, a total of 11,551 patients were diagnosed with CRC at 
Severance Hospital, Seoul, Korea. Diagnosis was made from surgical excision or tissue biopsy. Inclusion criteria 
were as follows: (1) age > 18 years, (2) histologically confirmed diagnosis of CRC, (3) radiologically or patho-
logically confirmed bone metastasis, and (4) available electronic medical records (including treatment informa-
tion). Patients with other histology types, such as neuroendocrine tumors, small cell carcinoma, melanoma, or 
lymphoma, were excluded. A total of 321 patients fulfilled the inclusion and exclusion criteria. The Severance 
Hospital Institutional Review Board (IRB) approved this retrospective study, and the requirement to obtain 
Figure 3.  Kaplan–Meier overall survival (OS) curves according to risk group defined by number of adverse 
prognostic factors: (A) low-risk (0 to 2 adverse factors) and high-risk (3 to 4 adverse factors) groups, (B) 
palliative chemotherapy in the low-risk patients, and (C) palliative chemotherapy in the high-risk patients.
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informed consent was waived. This study was conducted in accordance with the Declaration of Helsinki and was 
consistent with Good Clinical Practice.
Data collection. To diagnose bone metastasis, plain radiography, technetium-99m methylene diphospho-
nate (Tc-99m MDP) whole body bone scintigraphy, CT scan, PET-CT and magnetic resonance imaging (MRI) 
were performed. All available correlative radiographic studies were reviewed. The following baseline data were 
recorded at the time of bone metastasis: age, sex, tumor location, histologic type, initial stage, metastatic organ, 
and KRAS mutation status. For tumor sidedness determination, the splenic flexure was used for differentiation 
of the left side of the colon and right side of the colon. KRAS mutation status was identified by Sanger sequenc-
ing, the peptide nucleic acid (PNA)-mediated PCR clamping  method19, or pyrosequencing. Sanger sequencing 
and the PNA-mediated PCR clamping method were used to detect mutations in codons 12 and 13. Pyrosequenc-
ing was performed to detect mutations at codons 12, 13, and 61. Metachronous bone metastasis was defined as 
the time to bone metastasis being greater than 3 months from initial CRC diagnosis.
Hematological and blood chemistry values included NLR, platelet count, ALP, and CEA. The NLR was cal-
culated by dividing the absolute neutrophil count by the absolute lymphocyte count. Parameters related to bone 
metastasis included time to bone metastasis, site of bone metastasis, and SREs defined by pathologic fracture, 
spinal cord compression, surgery to bone, radiotherapy to bone, and hypercalcemia. After the diagnosis of bone 
metastasis, whether patients received palliative chemotherapy was also reviewed.
Statistical analysis. The demographic and clinical characteristics were compared using the Chi square or 
Fisher exact test. The Mann–Whitney U test was used for comparisons of continuous variables. In patients with 
metachronous bone metastasis, freedom from bone metastasis since CRC diagnosis was estimated using the 
Kaplan–Meier method. Overall survival (OS) was defined as the time from the date of bone metastasis diagnosis 
to death from any cause. Hematological and blood chemistry values were initially recorded as continuous vari-
ables and later transformed into categorical variables according to lower or upper normal values (platelet count, 
ALP level, and CEA level) or the best cut-off point (NLR) determined by the Contal and O’Quigley method, 
which calculates the maximization of the hazard ratio based on log rank statistics and estimates the best cut-off 
 value20. Survival curves were generated using the Kaplan–Meier method and compared using the log-rank test.
Univariate analysis was performed to determine associations of OS with the following prognostic factors: age; 
sex; tumor location and sidedness; timing of bone metastasis (synchronous or metachronous); histologic type; 
bone metastasis pattern (bone-only or not); liver, lung, peritoneal, and/or brain metastasis; NLR; ALP level; CEA 
level; KRAS mutation status; and palliative chemotherapy treatment. A stepwise multivariate analysis with Cox 
proportional hazard model was performed using significant factors from the univariate analysis. Hazard ratio 
(HR), 95% CI, and χ2 scores were obtained for all regressions. Statistical analyses were performed using PASW 
Statistics 18.0 (SPSS Inc., Chicago, IL, USA), SAS version 9.2 (SAS institute, Cary, NC, USA), and R version 3.1.3 
(Institute for Statistics and Mathematics, Vienna, Austria www.R-proje ct.org).
Data availability
Upon reasonable request, data and material are available from the corresponding authors.
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